

# David F Claxton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2016632/publications.pdf>

Version: 2024-02-01

85  
papers

2,059  
citations

331670

21  
h-index

254184

43  
g-index

86  
all docs

86  
docs citations

86  
times ranked

3539  
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel clinically relevant graft-versus-leukemia model in humanized mice. <i>Journal of Leukocyte Biology</i> , 2022, 111, 427-437.	3.3	4
2	Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications. <i>Stem Cell Reviews and Reports</i> , 2022, 18, 1211-1226.	3.8	8
3	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-immunotherapy. <i>British Journal of Haematology</i> , 2022, , .	2.5	0
4	Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. <i>Blood Reviews</i> , 2022, 55, 100950.	5.7	9
5	Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia. <i>FASEB Journal</i> , 2022, 36, e22094.	0.5	7
6	Interleukin-4 treatment reduces leukemia burden in acute myeloid leukemia. <i>FASEB Journal</i> , 2022, 36, e22328.	0.5	7
7	Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. <i>Journal of Hematology and Oncology</i> , 2022, 15, 64.	17.0	24
8	A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2021, 96, E46-E50.	4.1	16
9	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	5.2	28
10	Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 1127.	3.7	12
11	Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. <i>Journal of Clinical Oncology</i> , 2021, 39, 1001-1009.	1.6	22
12	HOXBLINE long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 1956.	12.8	28
13	Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion. <i>Annals of Hematology</i> , 2021, 100, 2585-2592.	1.8	2
14	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	4.1	4
15	DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 4889.	3.7	4
16	Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. <i>Blood</i> , 2021, 138, 413-413.	1.4	1
17	Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152. <i>Blood</i> , 2021, 138, 3407-3407.	1.4	5
18	Engraftment Kinetics and Recipient Chimerism Increase to Predict Leukemia Relapse By Ptcy and Non-Ptcy Transplant. <i>Blood</i> , 2021, 138, 1792-1792.	1.4	0

#	ARTICLE	IF	CITATIONS
19	DJ4 Targets Rho-associated Protein Kinase Pathway and Attenuates Disease Progression in Pre-clinical Murine Models of Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3350-3350.	1.4	0
20	The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, 687-696.	3.5	14
21	Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. <i>British Journal of Haematology</i> , 2020, 188, 674-684.	2.5	12
22	Ceramide Analogue SACLAC Modulates Sphingolipid Levels and <i>MCL-1</i> Splicing to Induce Apoptosis in Acute Myeloid Leukemia. <i>Molecular Cancer Research</i> , 2020, 18, 352-363.	3.4	22
23	Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. <i>Blood</i> , 2020, 136, 1067-1079.	1.4	18
24	AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. <i>Experimental Hematology</i> , 2020, 87, 13-19.	0.4	12
25	The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 393.	2.8	14
26	<i>Hottip</i> -Mediated R-Loops Regulate CTCF TAD Boundary to Control WNT/ $\beta$ -Catenin Pathway in AML Genome. <i>Blood</i> , 2020, 136, 44-45.	1.4	0
27	Eomes <sup>+</sup> T-bet <sup>low</sup> CD8 <sup>+</sup> T Cells Are Functionally Impaired and Are Associated with Poor Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Cancer Research</i> , 2019, 79, 1635-1645.	0.9	42
28	Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant—a pilot study. <i>British Journal of Haematology</i> , 2019, 186, e130-e133.	2.5	9
29	Downregulation of CD73 associates with T cell exhaustion in AML patients. <i>Journal of Hematology and Oncology</i> , 2019, 12, 40.	17.0	25
30	Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF- $\kappa$ B-dependent P-glycoprotein upregulation. <i>Journal of Lipid Research</i> , 2019, 60, 1078-1086.	4.2	31
31	Therapy of acute myeloid leukemia: therapeutic targeting of tyrosine kinases. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 337-349.	4.1	13
32	Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 2598-2603.	5.2	24
33	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019, 133, 1548-1559.	1.4	292
34	Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity. <i>Oncolimmunology</i> , 2019, 8, e1539614.	4.6	17
35	Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients. <i>Blood</i> , 2019, 134, 3939-3939.	1.4	2
36	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. <i>Blood</i> , 2019, 134, 115-115.	1.4	19

#	ARTICLE	IF	CITATIONS
37	An Integrated Framework for Genome Analysis Reveals Numerous Previously Unrecognizable Structural Variants in Leukemia Patient Samples. <i>FASEB Journal</i> , 2019, 33, 474.1.	0.5	1
38	Non-Myeloablative Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia: Graft-Versus-Host Disease Potentiates Graft-Versus-Leukemia Effect and Improves Overall Survival. <i>Blood</i> , 2019, 134, 5724-5724.	1.4	0
39	Therapeutic effect of Northern Labrador tea extracts for acute myeloid leukemia. <i>Phytotherapy Research</i> , 2018, 32, 1636-1641.	5.8	7
40	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. <i>Cell Cycle</i> , 2018, 17, 468-478.	2.6	34
41	VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML. <i>Oncolmmunology</i> , 2018, 7, e1469594.	4.6	107
42	Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. <i>Blood Cancer Journal</i> , 2018, 8, 34.	6.2	48
43	TIGIT Expression Positively Associates with NK Cell Function in AML Patients. <i>Blood</i> , 2018, 132, 5250-5250.	1.4	5
44	Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial. <i>Blood</i> , 2018, 132, 437-437.	1.4	4
45	FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years. <i>Blood</i> , 2018, 132, 3995-3995.	1.4	3
46	The Novel Small Molecule Inhibitor KS99 Targets AML and Inhibits Stemness Markers STAT3 and ALDH. <i>Blood</i> , 2018, 132, 1440-1440.	1.4	0
47	Multi-Dimensional Analysis of Immune Signature Predicts Response to Decitabine Treatment in Elderly Patients with AML. <i>Blood</i> , 2018, 132, 1526-1526.	1.4	13
48	Therapeutic Effect of Blueberry Extracts for Acute Myeloid Leukemia. , 2018, 1, .		5
49	Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia. , 2018, 1, .		3
50	Therapeutic inhibition of BCL-2 and related family members. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 293-301.	4.1	18
51	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1&sup2; study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	10.7	402
52	Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 124.	17.0	42
53	Myeloid Sarcoma of the Thyroid. <i>Ear, Nose and Throat Journal</i> , 2017, 96, 460-461.	0.8	2
54	PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features. <i>Oncotarget</i> , 2017, 8, 29887-29905.	1.8	9

#	ARTICLE	IF	CITATIONS
55	Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability. PLoS ONE, 2017, 12, e0173723.	2.5	29
56	SKI-178: A multitargeted inhibitor of sphingosine kinase and microtubule dynamics demonstrating therapeutic efficacy in acute myeloid leukemia models. Cancer Translational Medicine, 2017, 3, 109.	0.2	27
57	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood, 2017, 130, 891-891.	1.4	6
58	Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model. Cell Death and Disease, 2016, 7, e2361-e2361.	6.3	51
59	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. Clinical Cancer Research, 2016, 22, 3057-3066.	7.0	217
60	Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). Blood, 2016, 128, 1069-1069.	1.4	35
61	Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. Blood, 2016, 128, 1166-1166.	1.4	5
62	The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma. Blood, 2016, 128, 1792-1792.	1.4	5
63	Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma. Blood, 2016, 128, 2759-2759.	1.4	1
64	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. Blood, 2016, 128, 3222-3222.	1.4	16
65	Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in CLL: Results from a Large Multi-Center Study of 683 US-Patients. Blood, 2016, 128, 4400-4400.	1.4	2
66	Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget, 2016, 7, 83208-83222.	1.8	73
67	Modification of sphingolipid metabolism by tamoxifen and N-desmethyldtamoxifen in acute myelogenous leukemia—Impact on enzyme activity and response to cytotoxics. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 919-928.	2.4	24
68	Intractable myoclonic seizures in an allogeneic stem cell transplant recipient: A rare case of myoclonic epilepsy. Epilepsy & Behavior Case Reports, 2015, 4, 48-51.	1.5	1
69	Phase I/II Study of Clofarabine, Etoposide, and Mitoxantrone in Patients With Refractory or Relapsed Acute Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 41-46.	0.4	9
70	Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2r $\beta$ null Mice for Preclinical Ceramide-Based Therapeutic Evaluation. Journal of Leukemia (Los Angeles, Calif ), 2014, 02, .	0.1	3
71	Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression. Cancer Biology and Therapy, 2014, 15, 1077-1086.	3.4	33
72	Extracts of Devil's Club (<i>Oplopanax horridus</i>) Exert Therapeutic Efficacy in Experimental Models of Acute Myeloid Leukemia. Phytotherapy Research, 2014, 28, 1308-1314.	5.8	9

#	ARTICLE	IF	CITATIONS
73	Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin's Lymphoma and Previously Untreated Mantle Cell Lymphoma. <i>Blood</i> , 2014, 124, 1714-1714.	1.4	7
74	Genome-wide mapping of large organized heterochromatin domains reveals hotspots of epigenetic and transcriptional changes associated with myeloid differentiation and acute myeloid leukemia (565.1). <i>FASEB Journal</i> , 2014, 28, 565.1.	0.5	1
75	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013, 122, 3903-3903.	1.4	35
76	Vorinostat (SAHA), Cladribine, and Rituximab in Previously Untreated Mantle Cell Lymphoma: Updated Results From a Phase I/II Trial. <i>Blood</i> , 2012, 120, 3675-3675.	1.4	1
77	Early Discharge and Out Patient Management After AML Induction Chemotherapy: Determinants of Safety. <i>Blood</i> , 2012, 120, 2054-2054.	1.4	0
78	Enhancing Ceramide Cytotoxicity in Acute Myelogenous Leukemia. <i>Blood</i> , 2012, 120, 4905-4905.	1.4	0
79	Out Foxing Bcr-Abl. <i>Cancer Biology and Therapy</i> , 2011, 11, 769-770.	3.4	0
80	Clofarabine, Etoposide and Mitoxantrone In the Therapy of Relapsed and Refractory Acute Myelogenous Leukemia. <i>Blood</i> , 2010, 116, 4353-4353.	1.4	17
81	Sirolimus as Primary Immunoprophylaxis for Alternative Donor Allograft after Non-Myeloablative Conditioning.. <i>Blood</i> , 2007, 110, 3069-3069.	1.4	0
82	Potent Anti-Leukemic Activity of a Cationic Lipid-DNA Complex.. <i>Blood</i> , 2007, 110, 4891-4891.	1.4	0
83	Non-Myeloablative Hematopoietic Transplant with Sirolimus Immunosuppression: Determinants of Outcome.. <i>Blood</i> , 2005, 106, 5462-5462.	1.4	0
84	Successful Treatment of Advanced and Refractory AML with Sirolimus Based Non-Myeloablative Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 2760-2760.	1.4	0
85	Autologous immunotherapy for human leukemias. <i>Blood Cells, Molecules, and Diseases</i> , 2003, 31, 121-124.	1.4	2